Abstracts tagged "quality of life"

Abstract Number: 1266 • ACR Convergence 2021
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
Meghan Nelson¹, Lori Ponder², Sinclair Gibson³, D. Sofia Villacis- Nunez¹, Lai Hin Kimi Chan³, Lakshmi Moorthy⁴ and Sampath Prahalad⁵, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood systemic lupus erythematosus (cSLE) is a life-long disease with significant morbidity and mortality, and with associated significant impact on health-related quality of life…
Abstract Number: 1668 • ACR Convergence 2021
Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort
Elizabeth Clarke¹, Claire Wood¹, Alistair Tindell¹, Kay Graham¹, Alasdair McIntosh², Fraser Morton² and Duncan Porter³, ¹NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³University of Glasgow, Bearsden, United Kingdom
Background/Purpose: ‘Treat to target’ strategies of care have significantly improved outcomes in people with early rheumatoid arthritis; nonetheless, a significant proportion of patients have impaired…
Abstract Number: 0749 • ACR Convergence 2021
Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
Xenofon Baraliakos¹, Louis Bessette², Carlo Salvarani³, Naijun Chen⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, In-Ho Song⁴, Patrick Zueger⁶ and Philippe Goupille⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Laval University, Québec City, QC, Canada, ³Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universita di Moderna e Reggio Emilia, Reggio Emilia, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷University hospital of Tours, Rheumatology department, Tours, France
Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 0754 • ACR Convergence 2021
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Shivani Garg¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with SLE have significantly worse health-related quality of life (QOL) at an earlier age compared to patients with other chronic diseases. This highlights…
Abstract Number: 1274 • ACR Convergence 2021
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil¹, Rocio Gamboa-Cardenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz¹, Mariela Medina⁴, Claudia Elera-Fitzcarrald², Francisco Zevallos⁴, Cesar Pastor-Asurza⁵, Federico Zazzetti⁶, Chetan Karyekar⁷, Risto Perich-Campos⁵ and Graciela Alarcn⁸, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁷Janssen R&D, Spring House, PA, ⁸University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flares in SLE patients, regardless of their severity, have been associated with damage accrual. However, their impact on HRQoL has not been fully evaluated.…
Abstract Number: 1786 • ACR Convergence 2021
Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab
Lars Erik Kristensen¹, Dennis McGonagle², Martin Rudwaleit³, Hideto Kameda⁴, Thorsten Holzkaemper⁵, Celine El Baou⁶ and Josef Smolen⁷, ¹Bispebjerg-Frederiksberg Hospital, Copenhagen,, Denmark, ²University of Leeds, Leeds, United Kingdom, ³Bielefeld University, Rheumatology, Klinikum Bielefeld, Berlin, Germany, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Eli Lilly and Company, Bad Homburg, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is an inflammatory rheumatic disease with manifestations including synovitis and enthesitis. During extensive study programs, IXE has shown a treatment effect across domains…
Abstract Number: 0122 • ACR Convergence 2021
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
Stephanie Catella¹, Michael Gendreau², Nicolette Vega¹, Allison Kraus¹, Michael Rosenbluth¹, Sherry Soefje³, Shishuka Malhotra⁴ and Lesley Arnold⁵, ¹Swing Therapeutics, San Francisco, CA, ²Gendreau Consulting, LLC, Poway, CA, ³Excell Research, Oceanside, CA, ⁴Neuro-Behavioral Clinical Research, North Canton, OH, ⁵University of Cincinnati, Cincinnati, OH
Background/Purpose: Recommendations for fibromyalgia management include both pharmacologic and nonpharmacologic treatments. Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for fibromyalgia management, though access…
Abstract Number: 0760 • ACR Convergence 2021
The Performance of RA Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis-Associated Interstitial Lung Disease in a Prospective Trial Using Pirfenidone in RA ILD (TRAIL1)
Paul Dellaripa¹, Tracy Doyle², Sonye Danoff³, Hillary Goldberg¹, Martin Kolb⁴, Daniel Chambers⁵, Felix Woodhead⁶, Cathy Spino⁷, Ivan Rosas⁸ and Joshua Solomon⁹, ¹Brigham and Women's, Boston, MA, ²Brigham and Women's Hospital, West Roxbury, MA, ³Johns Hopkins Medicine, Baltimore, MD, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Queensland, Brisbane St Lucia, Australia, ⁶University of Leicester, Leicester, United Kingdom, ⁷University of Michigan, Ann Arbor, MI, ⁸Baylor College of Medicine, Houston, TX, ⁹National Jewish Health, Denver, CO
Background/Purpose: Both rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF) have established measures of disease severity and patient reported outcomes (PROs) that measure health-related quality…
Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 0223 • ACR Convergence 2021
The Association of Clinical and Structural Knee Osteoarthritis with Physical Activity in the Middle-aged Population: The Netherlands Epidemiology of Obesity Study
Sietse Terpstra¹, Jeroen van der Velde¹, Renée de Mutsert¹, Dieuwke Schiphof², Monique Reijnierse¹, Frits Rosendaal¹, Lotte van de Stadt¹, Margreet Kloppenburg¹ and Marieke Loef¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Physical activity is a potential target for interventions in knee OA. However, most of the available studies concerning physical activity in individuals with knee…
Abstract Number: 0773 • ACR Convergence 2021
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Ly-Lan Bergeron², Samantha Dill², MIchelle O'Brien², Xiaobai Li³, Jomy George³, April Brundidge², Michelle Millwood², Lisa Rider⁴ and Robert Colbert⁵, ¹Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, ²Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH/NIAMS, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].